Lupin's Nagpur unit-1 receives favorable FDA inspection report

Global pharmaceutical giant Lupin Limited (Lupin) has received a significant validation from the United States Food and Drug Administration (U.S. FDA). Lupin announced, that it has obtained the Establishment Inspection Report (EIR) for its Nagpur Unit-1 manufacturing facility, which specializes in the production of oral solid dosage forms.
 

The EIR was issued following the facility's latest inspection conducted in July 2023, and the U.S. FDA has classified the inspection as "Voluntary Action Indicated" (VAI). This favorable classification reflects Lupin's unwavering commitment to maintaining the highest standards of quality and compliance.

Nilesh Gupta, Managing Director of Lupin, expressed his satisfaction with the achievement, emphasizing Lupin's dedication to delivering top-quality healthcare solutions to patients worldwide. This positive development is a testament to Lupin's continuous efforts to ensure the integrity of its manufacturing processes and adherence to regulatory standards.